Advertisement
Canada markets close in 1 hour 36 minutes

  • S&P/TSX

    21,793.88
    +85.44 (+0.39%)
     

  • S&P 500

    4,979.10
    -32.02 (-0.64%)
     

  • DOW

    37,966.94
    +191.56 (+0.51%)
     

  • CAD/USD

    0.7273
    +0.0010 (+0.13%)
     

  • CRUDE OIL

    83.31
    +0.58 (+0.70%)
     

  • Bitcoin CAD

    88,596.09
    +2,394.92 (+2.78%)
     

  • CMC Crypto 200

    1,383.11
    +70.49 (+5.37%)
     

  • GOLD FUTURES

    2,408.70
    +10.70 (+0.45%)
     

  • RUSSELL 2000

    1,942.55
    -0.41 (-0.02%)
     

  • 10-Yr Bond

    4.6250
    -0.0220 (-0.47%)
     

  • NASDAQ

    15,346.50
    -254.99 (-1.63%)
     

  • VOLATILITY

    18.62
    +0.62 (+3.45%)
     

  • FTSE

    7,895.85
    +18.80 (+0.24%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • CAD/EUR

    0.6825
    +0.0004 (+0.06%)
     
MARKETS LIVE BLOG:

S&P 500 SLIPS BELOW 5,000; NASDAQ SINKS ON NETFLIX DRAG

Fed's Goolsbee says 'It makes sense to wait' before cutting rates

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of ChemoCentryx, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of July 6, 2021 - CCXI

Newsfile Corp.
·2 min read

New York, New York--(Newsfile Corp. - May 7, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of ChemoCentryx, Inc. ("ChemoCentryx") (NASDAQ: CCXI) between November 26, 2019 and May 3, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Northern District of California. To get more information go to:

https://www.zlk.com/pslra-1/chemocentryx-inc-loss-submission-form?prid=15617&wire=5

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.

The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) the study design of the Phase III ADVOCATE trial presented issues about the interpretability of the trial data to define a clinically meaningful benefit of avacopan and its role in the management of ANCA-associated vasculitis; (2) the data from the Phase III ADVOCATE trial raised serious safety concerns for avacopan; (3) these issues presented a substantial concern regarding the viability of ChemoCentryx's New Drug Application ("NDA") for avacopan for the treatment of ANCA-associated vasculitis; and (4) as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.

ADVERTISEMENT

If you suffered a loss in ChemoCentryx you have until July 6, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/83378